Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has ...

Human lung alveolus chip infection model enables investigation of viral replication, inflammatory responses, and genetic ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies ...

Our experiences leave traces in the brain, stored in small groups of cells called "engrams". Engrams are thought to hold the information of a memory ...

Importantly, the researchers at Boston Children's Hospital utilized the Nabsys OhmX Platform to identify a ...

Colorectal cancer (CRC) remains one of the most prevalent cancers worldwide and a leading cause of cancer mortality. Despite ...

Q3 2025 Earnings Call October 28, 2025 8:30 AM EDTCompany ParticipantsJacob JohnsonOlivier Loeillot - President, ...

Robust efficacy data: ≥90% LDL-C reduction in non-human primates achieved within 48 hours of a single dose of EDIT-401; ≥90% LDL-C reduction in mice with high baseline LDL-C and reduced LDLR function ...

Overview of Whole Genome Synthesis MarketThe global Whole Genome Synthesis Market is valued at USD 2.41 Billion in 2024 and is projected to reach a value of USD 12.21 Billion by 2035 at a CAGR ...

The global regenerative medicine market is poised for remarkable expansion, expected to record a compound annual growth rate (CAGR) of around 17% during the forecast period. This surge is primarily ...

The Summer Research Showcase featured work that ranged from advancing cancer treatments to improving health care access. More ...

Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the ...